Systematic Review

Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study

Alessandro Rizzo 1,†, Veronica Mollica 2,3,†, Andrea Marchetti 2,†, Giacomo Nuvola 2,†, Matteo Rosellini 2,†, Elisa Tassinari 2, Javier Molina-Cerrillo 4,†, Zin W. Myint 5,†, Tomas Buchler 6,‡, Fernando Sabino Marques Monteiro 7,8,9,‡, Enrique Grande 10,‡, Matteo Santoni 11,‡ and Francesco Massari 2,3,*,†

1 Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico “Don Tonino Bello”, Istituto di Ricerca e Cur a Carattere Scientifico (IRCCS), Istituto Tumori Giovanni Paolo II-Bari, Viale Orazio Flacco 65, 70124 Bari, Italy
2 Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
3 Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, University of Bologna, 40138 Bologna, Italy
4 Department of Medical Oncology, Hospital Ramón y Cajal, 28034 Madrid, Spain
5 Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0293, USA
6 Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, 14059 Prague, Czech Republic
7 Hospital Santa Lucia, Brasilia 70390-700, Brazil
8 Hospital Universitário de Brasília, Brasilia 70840-901, Brazil
9 Latin American Cooperative Oncology Group-LACOG, Porto Alegre 90619-900, Brazil
10 Department of Medical Oncology, MD Anderson Cancer Center Madrid, 28033 Madrid, Spain
11 Oncology Unit, Macerata Hospital, via Santa Lucia 2, 62100 Macerata, Italy
* Correspondence: francesco.massari@aosp.bo.it
† These authors contributed equally to this work.
‡ These authors contributed equally to this work.

Simple Summary: Despite a significant improvement in clinical outcomes and the emergence of novel and potentially curative strategies, a noticeable number of oncological patients witness a disease relapse after surgery. Adjuvant treatments have been developed to reduce the risk of recurrence and gain survival benefits for these patients. The aim of this meta-analysis was to explore the impact of adjuvant PD-1/PD-L1 inhibitors on relapse-free survival in cancer patients with many solid tumors. We confirmed that PD-1/PD-L1 inhibitors may reduce the risk of relapse in many tumor types, compared to control treatments. Moreover, we showed that the benefit was consistent in subgroups divided according to gender and age.

Abstract: Background: Adjuvant treatment has always been a cornerstone in the therapeutic approach of many cancers, considering its role in reducing the risk of relapse and, in some cases, increasing overall survival. Adjuvant immune checkpoint inhibitors have been tested in different malignancies. Methods: We performed a meta-analysis aimed to explore the impact of adjuvant PD-1 and PD-L1 inhibitors on relapse-free survival (RFS) in cancer patients enrolled in randomized controlled clinical trials. We retrieved all phase III trials published from 15 June 2008 to 15 May 2022, evaluating PD-1/PD-L1 inhibitors monotherapy as an adjuvant treatment by searching on EMBASE, Cochrane Library, and PubMed/ Medline, and international oncological meetings’ abstracts. The outcome of interest was RFS. We also performed subgroup analyses focused on age and gender. Results: Overall, 8 studies, involving more than 6000 patients, were included in the analysis. The pooled results highlighted that the use of adjuvant PD-1/PD-L1 inhibitors may reduce the risk of relapse compared to control treatments (hazard ratio, 0.72; 95% confidence intervals, 0.67–0.78). In addition, the subgroup analyses observed that this benefit was consistent in different patient populations, including male, female, younger, and older patients. Conclusions: Adjuvant anti-PD-1/PD-L1 treatment is associated with an increased RFS in the overall population and in subgroups divided according to age and gender.
Keywords: adjuvant; immunotherapy; immune checkpoint inhibitors; PD-1; relapse-free survival

1. Introduction

Despite the fact that the last two decades have seen the improvement of clinical outcomes and the emergence of novel, potentially curative treatment options, a notable proportion of cancer patients experience disease relapse after radical surgery. As a result, adjuvant anticancer therapies have been developed to lower the risk for recurrence and to improve overall survival. Among these, recent years have seen the emergence of anticancer immunotherapy, which represents a standard for the management of a wide spectrum of metastatic solid tumors, ranging from malignant melanoma to non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and urothelial carcinoma (UC) [1–5]. Immune checkpoint inhibitors (ICIs) target the immune checkpoints on T-lymphocytes and regulate the function of the anticancer immune response through molecular mechanisms [6,7]; cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell death-1 (PD-1), and its ligands PD-L1 and PD-L2 represent the most frequently used ICIs target, something that has led to the development of specific inhibitors, such as—among others—pembrolizumab, nivolumab, durvalumab, atezolizumab, and avelumab [8]. Following the practice-changing results observed in clinical trials evaluating ICIs, these agents have been assessed and are currently under investigation in the earlier stages of disease, including adjuvant treatment [9–16]. Adjuvant immunotherapy is administered following resection surgery, with ICIs increasing the frequency of activated T cells that have been suggested to be able to eliminate tumor cells after radical resection [17,18]. However, the use of immunotherapy in the adjuvant setting raises several questions, including the duration of treatment, the selection of appropriate comparators; the sequencing of therapies (especially in tumors with targetable mutations, such as melanoma); and the safety profile of these agents, a key point to consider after potentially curative surgery. At the same time, several trials with available data lack overall survival results and a mature follow-up.

Based on these premises, we performed a comprehensive and up-to-date meta-analysis aiming to evaluate the impact of adjuvant PD-1 and PD-L1 inhibitors on relapse-free survival (RFS) in cancer patients. Subgroup analyses exploring the role of gender and age were also performed.

2. Materials and Methods

2.1. Search Strategy

All phase III clinical trials published from June 15th, 2008, to May 15th, 2022, assessing anti-PD-1 and anti-PD-L1 agents’ monotherapy as adjuvant treatment in cancer patients, were retrieved by three different authors. Keywords used for searching on EMBASE, Cochrane Library, and PubMed/ Medline were as follows: “cancer” OR “solid tumor” AND “atezolizumab” OR “avelumab” OR “durvalumab” OR “immune checkpoint inhibitor” OR “nivolumab” OR “PD-1” OR “PD-L1” OR “pembrolizumab” OR “Programmed death receptor-1” OR “immunotherapy”. Articles published in peer-reviewed journals and written in English language were included, and the proceedings of the main meetings were also searched for relevant reports.

2.2. Selection Criteria

Trials retrieved from the first analysis we conducted were subsequently restricted to: (1) prospective phase III clinical trials in cancer patients; (2) participants receiving adjuvant treatment with PD-1 or PD-L1 inhibitors; (3) studies with available data in terms of RFS; and (4) studies with available data in male, female, elderly, and younger patients.
2.3. Data Extraction

The following data were extracted for each publication: (1) general trial information; (2) treatment arms; (3) the number of cancer patients; and (4) the available outcomes in terms of RFS in patients treated with anti-PD-1 or PD-L1 agents. The analysis was conducted according to Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines (Supplementary Materials) [19].

2.4. Risk of Bias Assessment in Included Studies

The Cochrane Collaboration tool was used to evaluate the methodological quality of the included studies; a risk of bias in the selected studies was assessed independently by three separate authors [20]. Trials examined were graded as having a “low risk”, “high risk”, or “unclear risk” of bias across the specified domains of selection, performance, attrition, and reporting bias. The results of the assessment were summarized in a risk of bias graph (Figure 1). The presence of publication bias was formally evaluated using funnel plots (Supplementary Materials).

![Risk of bias graph](image)

Figure 1. Risk of bias graph, with each risk of bias item reported as a percentage across all included trials.

2.5. Statistical Design

ProMeta 3 software was used to perform all the statistical analyses. Hazard ratios (HRs) and 95% confidence intervals (CIs) were the effect measures for RFS, and these values were extracted from available studies. Forest plots were used to assess HRs to describe the relationship between treatment and RFS in the specified cohorts of patients. Statistical heterogeneity between trials was examined using the Chi-square test and the I² statistic; substantial heterogeneity was considered to exist when the I² value was greater than 50% or there was a low p value (<0.10) in the Chi-square test [21]. We applied the fixed effects model when no heterogeneity was noted, while the random effects model was used in the case of significant heterogeneity.

3. Results

3.1. Selected Studies

2395 potentially relevant reports were identified; these reports were later restricted to eight following the independent evaluation of three authors [9–16]; 2387 records were excluded as non-pertinent reports. Eligible studies were identified and selected as shown in Figure 2; a summary of the included trials is presented in Table 1 [9–16]. The eight studies included in the meta-analysis compared adjuvant PD-1 or PD-L1 inhibitors monotherapy in cancer patients, involving more than 6000 patients [9–16]. In particular, these studies included patients with melanoma, UC, esophageal or gastroesophageal junction cancer, NSCLC, and RCC. Experimental treatment included atezolizumab, nivolumab, and pembrolizumab.
Figure 2. Figure reporting all the trials included and excluded in the quantitative synthesis.

Table 1. Summary of the included studies. Abbreviations: RFS: recurrence-free survival; HR: hazard ratio; CI: confidence interval; and ITT: intention-to-treat.

| Trial Name (Reference) | Year of Publication | Primary Tumor | Arms Experimental Control | Number of Patients | RFS | HR (CI) p |
|------------------------|---------------------|---------------|---------------------------|--------------------|-----|-----------|
| CheckMate 238 [9]      | 2020                | Melanoma      | Nivolumab | 906 | 4-year RFS: 51.7% | HR 0.72 (95% CI 0.60–0.86) | p = 0.0003 |
|                        |                     |               | Ipilimumab |                | 41.2% |           |
| KEYNOTE-054 [15]       | 2021                | Melanoma      | Pembrolizumab | 1019 | 1-year RFS ITT: 75.4% | HR 0.56 (98.4% CI 0.43–0.74) | p < 0.0001 |
|                        |                     |               | Placebo |                | 61.0% |           |
| IMMUNED [12]           | 2020                | Melanoma      | Nivolumab | 167 | 12.4 months | HR 0.56 (95% CI 0.33–0.94) | p = 0.011 |
|                        |                     |               | Placebo |                | 6.4 months |           |
| CheckMate 577 [11]     | 2021                | Esophageal or gastro-esophageal junction cancer | Nivolumab | 794 | 22.4 months | HR 0.69 (96.4% CI 0.56–0.86) | p < 0.001 |
|                        |                     |               | Placebo |                | 11.0 months |           |
| IMpower010 [13]        | 2021                | Non-small cell lung cancer | Atezolizumab | 1280 | All patients: 42.3 months | HR 0.78 (95% CI 0.64–0.96) | p = 0.020 |
|                        |                     |               | Best supportive care | | 35.3 months |           |
| IMvigot010 [14]        | 2021                | Urothelial carcinoma | Atezolizumab | 809 | 19.4 months | HR 0.89 (95% CI 0.74–1.08) | p = 0.24 |
|                        |                     |               | Observation |                | 16.6 months |           |
| CheckMate 274 [10]     | 2021                | Urothelial carcinoma | Nivolumab | 709 | 20.8 months | HR 0.79 (95% CI 0.57–0.84) | | |
|                        |                     |               | Placebo |                | 10.8 months |           |
| KEYNOTE-564 [16]       | 2021                | Renal cell carcinoma | Pembrolizumab | 994 | 24-months RFS: 77.3% | HR 0.68 (95% CI 0.53–0.87) | p = 0.002 |
|                        |                     |               | Placebo |                | 68.1% |           |
3.2. Relapse-Free Survival

The pooled HR for RFS was 0.72 (95% CI, 0.67–0.78), suggesting that patients receiving adjuvant PD-1 or PD-L1 inhibitors presented longer RFS (Figure 3); the analysis was associated with low heterogeneity (I² of 31%); thus, a fixed-effects model was used.

| ES     | 95% CI   | W     |
|--------|----------|-------|
| CheckMate 238 | 0.72     | 0.60 / 0.86 | 18.70% |
| CheckMate 274 | 0.69     | 0.57 / 0.84 | 16.12% |
| CheckMate 577 | 0.69     | 0.56 / 0.86 | 13.17% |
| IMMUNE     | 0.56     | 0.33 / 0.94 | 2.21%  |
| IMpower010 | 0.78     | 0.64 / 0.96 | 14.74% |
| IMvigor010 | 0.89     | 0.74 / 1.08 | 16.96% |
| KEYNOTE-054 | 0.56     | 0.43 / 0.74 | 8.22%  |
| KEYNOTE-564 | 0.68     | 0.53 / 0.87 | 9.87%  |
| Overall (fixed-effect model) | 0.72     | 0.67 / 0.78 | 100.00% |

Figure 3. Forest plot of comparison between adjuvant PD-1 and PD-L1 inhibitors versus control (placebo/ipilimumab/observation/best supportive care) in cancer patients; the outcome of interest was relapse-free survival (RFS) in the intention-to-treat population. Abbreviations: CI: confidence interval; ES: effect size; and W: weight.

3.3. Relapse-Free Survival According to Gender

The pooled HRs for RFS in male and female patients were 0.74 (95% CI, 0.67–0.81) and 0.73 (95% CI, 0.63–0.84) (Figure 4, Figure 5); the two analyses reported low heterogeneity (I² of 22 and 28%, respectively), and thus a fixed-effects model was used.

| ES     | 95% CI   | W     |
|--------|----------|-------|
| CheckMate 238 | 0.74     | 0.59 / 0.93 | 16.71% |
| CheckMate 274 | 0.68     | 0.53 / 0.86 | 14.77% |
| CheckMate 577 | 0.73     | 0.59 / 0.91 | 18.43% |
| IMMUNE     | 0.78     | 0.44 / 1.38 | 2.65%  |
| IMpower010 | 0.76     | 0.59 / 0.99 | 12.92% |
| IMvigor010 | 0.91     | 0.73 / 1.13 | 18.13% |
| KEYNOTE-054 | 0.53     | 0.37 / 0.76 | 6.68%  |
| KEYNOTE-564 | 0.66     | 0.49 / 0.89 | 9.72%  |
| Overall (fixed-effect model) | 0.74     | 0.67 / 0.81 | 100.00% |

Figure 4. Forest plot of comparison between adjuvant PD-1 and PD-L1 inhibitors versus control (placebo/ipilimumab/observation/best supportive care) in cancer patients; the outcome of interest was relapse-free survival (RFS) in male patients. Abbreviations: CI: confidence interval; ES: effect size; and W: weight.

| ES     | 95% CI   | W     |
|--------|----------|-------|
| CheckMate 238 | 0.70     | 0.52 / 0.93 | 22.96% |
| CheckMate 274 | 0.99     | 0.65 / 1.52 | 10.76% |
| CheckMate 577 | 0.59     | 0.35 / 1.00 | 7.04%  |
| IMMUNE     | 0.59     | 0.35 / 1.00 | 7.04%  |
| IMpower010 | 0.80     | 0.57 / 1.13 | 16.56% |
| IMvigor010 | 0.99     | 0.65 / 1.52 | 10.75% |
| KEYNOTE-054 | 0.53     | 0.37 / 0.76 | 14.97% |
| KEYNOTE-564 | 0.75     | 0.48 / 1.16 | 9.96%  |
| Overall (fixed-effect model) | 0.73     | 0.63 / 0.84 | 100.00% |

Figure 5. Forest plot of comparison between adjuvant PD-1 and PD-L1 inhibitors versus control (placebo/ipilimumab/observation/best supportive care) in cancer patients; the outcome of interest was relapse-free survival (RFS) in female patients. Abbreviations: CI: confidence interval; ES: effect size; and W: weight.
3.4. Relapse-Free Survival According to Age

The pooled HRs for RFS in younger (<65 years) and elderly (equal or more than 65 years) cancer patients were 0.70 (95% CI, 0.63–0.77) and 0.81 (95% CI, 0.71–0.92) (Figure 6, Figure 7); the two analyses reported low heterogeneity (I² of 17 and 19%, respectively), and thus a fixed-effects model was used.

| Study          | ES     | 95% CI      | W    |
|----------------|--------|-------------|------|
| CheckMate 238  | 0.72   | 0.58 / 0.89 | 23.04%|
| CheckMate 274  | 0.76   | 0.54 / 1.06 | 9.29% |
| CheckMate 577  | 0.65   | 0.51 / 0.84 | 16.97%|
| IMMUNED        | 0.48   | 0.28 / 0.83 | 3.58% |
| IMpower010     | 0.79   | 0.61 / 1.03 | 15.39%|
| IMvigor010     | 0.83   | 0.61 / 1.12 | 11.44%|
| KEYNOTE-054    | 0.57   | 0.41 / 0.80 | 9.45% |
| KEYNOTE-564    | 0.62   | 0.45 / 0.84 | 10.84%|
| Overall (fixed-effect model) | 0.70 | 0.63 / 0.77 | 100.00% |

**Figure 6.** Forest plot of comparison between adjuvant PD-1 and PD-L1 inhibitors versus control (placebo/ipilimumab/observation/best supportive care) in cancer patients; the outcome of interest was relapse-free survival (RFS) in younger patients. Abbreviations: CI: confidence interval; ES: effect size; and W: weight.

| Study          | ES     | 95% CI      | W    |
|----------------|--------|-------------|------|
| CheckMate 238  | 0.71   | 0.51 / 1.00 | 13.96%|
| CheckMate 274  | 0.76   | 0.54 / 1.06 | 13.91%|
| CheckMate 577  | 0.80   | 0.57 / 1.12 | 13.87%|
| IMMUNED        | 0.78   | 0.35 / 1.74 | 2.46% |
| IMpower010     | 0.75   | 0.54 / 1.05 | 14.31%|
| IMvigor010     | 1.01   | 0.79 / 1.29 | 26.31%|
| KEYNOTE-054    | 0.55   | 0.32 / 0.93 | 5.56% |
| KEYNOTE-564    | 0.84   | 0.56 / 1.26 | 9.62% |
| Overall (fixed-effect model) | 0.81 | 0.71 / 0.92 | 100.00% |

**Figure 7.** Forest plot of comparison between adjuvant PD-1 and PD-L1 inhibitors versus control (placebo/ipilimumab/observation/best supportive care) in cancer patients; the outcome of interest was relapse-free survival (RFS) in elderly patients. Abbreviations: CI: confidence interval; ES: effect size; and W: weight.

3.5. Publication Bias

The funnel plots of RFS in trials comparing adjuvant PD-1 and PD-L1 inhibitors versus control treatments included in our analysis showed basic symmetric, suggesting no publication bias (Supplementary Table S1, Figures S1–S5).

4. Discussion

Adjuvant ICIs aim to eliminate residual microscopic tumor cells via the immune system, in order to reduce the risk of cancer recurrence and to improve the chance of cure [22,23]. However, only some solid tumors benefit from this treatment approach, and better knowledge of the mechanisms leading to tumor escape and the impact of factors such as tumor microenvironment on the efficacy of immunotherapy is considered crucial for the optimal management of adjuvant ICIs [24,25]. In fact, a strong, relevant interplay between the tumor microenvironment and immune response has been highlighted in recent years, and this relationship may be particularly important in this setting. As in the case of other anticancer agents, some reflections regarding the efficacy of adjuvant ICIs in only some
tumors come to mind. A question may be if we are treating the wrong patients or if we are using the wrong drugs. As regards the first point, the identification of cancer patients that are at particularly high risk for recurrence, and which may benefit from adjuvant ICIs, is a key challenge. Similarly, if clinicians and researchers are testing and using the wrong drugs, another possible challenge would be to identify agents able to achieve higher objective response rates. These two points may be both fundamental in the current and future study design of adjuvant immunotherapy.

Herein, we performed a meta-analysis aimed to explore the impact of adjuvant PD-1 and PD-L1 inhibitors on RFS in cancer patients included in randomized controlled clinical trials. To the best of the authors’ knowledge, the current study represents the most updated meta-analysis specifically focused on this important and still commonly overlooked topic in current and future cancer management [9–16]. The pooled results highlighted that the use of adjuvant PD-1 and PD-L1 inhibitors may reduce the risk of relapse compared to patients receiving control treatments (HR, 0.72; 95% CI, 0.67–0.78). In addition, the subgroup analyses observed that this benefit was consistent in different patient populations, including male, female, younger, and older cancer patients. In order to reduce heterogeneity and to increase the statistical power of the current study, the analysis included only PD-1 and PD-L1 inhibitors. The PD-1 pathway represents one of the most important checkpoint pathways; with PD-1, which is expressed on the surface of T cells and binds to its ligands, we are hesitant regarding the inactivation of the T cells’ immune response, and we choose to include only these antagonists targeting PD-L1 or PD-1.

Our meta-analysis presents some strengths and limitations to be noticed. Among the strengths of this study, our analysis included eight controlled clinical trials by using the most updated data in terms of RFS in the intention-to-treat population and in specific subgroups. In addition, we included an overall large number of cancer patients treated with adjuvant immunotherapy. At the same time, some limitations should be underlined. Among these, the current study was based on pooled data, and it was not possible to include single-patient variables. In addition, the studies evaluated different immunotherapeutic agents. All these drugs present different efficacy profiles, an element that could have produced some bias. Moreover, a key point to consider is the inclusion of heterogeneous solid tumors, and the paucity of trials exploring ICIs in each cancer, makes it difficult to draw any reliable conclusions regarding adjuvant immunotherapy in specific cancer types. In fact, due to the diversity of tumor types and adjuvant therapies—as well as the overall limited number of trials—it was not possible to conduct a subgroup analysis on specific cancers. We believe our findings may help guide the everyday treatment decision-making of cancer patients treated with adjuvant PD-1 and PD-L1 inhibitors and assist in the design and interpretation of future studies exploring the role of adjuvant immunotherapy.

5. Conclusions

Adjuvant treatment with anti-PD-1 or -PD-L1 is associated with an increased RFS in multiple types of cancer. The results of this meta-analysis confirm the benefit of adjuvant ICIs by taking into account a wide number of patients. Gender and age differences did not affect the RFS benefit; this was confirmed in all subgroups. In future trial design, patients’ selection, which remains the key process to allow these compounds to exert their real value in prolonging survival outcomes, should be improved to individuate specific factors that could implement an immunotherapy response.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers14174142/s1, Figure S1: Funnel plot of relapse-free survival (RFS) in the intention-to-treat population; Figure S2: Funnel plot of relapse-free survival (RFS) in male cancer patients; Figure S3: Funnel plot of progression-free survival (PFS) in female cancer patients; Figure S4: Funnel plot of progression-free survival (PFS) in younger cancer patients; Figure S5: Funnel plot of progression-free survival (PFS) in elderly cancer patients; Table S1: PRISMA 2009 Checklist. Reference [26] is cited in Supplementary Materials.
Cancers 2022, 14, 4142

Author Contributions: Conceptualization, F.M. and M.S.; methodology, A.R., V.M., F.M. and M.S.; validation, all authors; formal analysis, A.R., V.M., F.M. and M.S.; investigation, all authors; data curation, all authors; writing—original draft preparation, A.R., V.M., F.M. and M.S.; writing—review and editing, A.R., V.M., F.M. and M.S.; supervision, F.M. and M.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: Francesco Massari reports personal fees from Astellas, Astra Zeneca, BMS, Janssen, Ipsen, MSD, and Pfizer, outside the submitted work. Tomas Buchler has received research support and honoraria from Roche, Bristol Myers Squibb, Merck Sharp Dohme, Merck, and AstraZeneca, all unrelated to the present paper. The other authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancy, honoraria, stock ownership or options, expert testimony, grants or patents pending, or royalties. No writing assistance was utilized in the production of this manuscript.

References
1. Llovet, J.M.; Kelley, R.K.; Villanueva, A.; Singal, A.G.; Pikarsky, E.; Roayaie, S.; Lencioni, R.; Koike, K.; Zucman-Rossi, J.; Finn, R.S. Hepatocellular Carcinoma. Nat. Rev. Dis. Prim. 2021, 7, 6. [CrossRef] [PubMed]
2. Reck, M.; Rodriguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csoszi, T.; Fülöp, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J. Clin. Oncol. 2019, 37, 537–546. [CrossRef] [PubMed]
3. Rizzo, A.; Mollica, V.; Santoni, M.; Ricci, A.D.; Rosellini, M.; Marchetti, A.; Montironi, R.; Ardizzoni, A.; Massari, F. Impact of Clinicalopathological Features on Survival in Patients Treated with First-Line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-Analysis of Randomized Clinical Trials. Eur. Urol. Focus 2022, 8, 514–521. [CrossRef]
4. Powles, T.; Park, S.H.; Voog, E.; Caserta, C.; Valderrama, B.P.; Gurney, H.; Kalofonos, H.; Radulović, S.; Demey, W.; Üllén, A.; et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N. Engl. J. Med. 2020, 383, 1218–1230. [CrossRef] [PubMed]
5. Massari, F.; Rizzo, A.; Mollica, V.; Rosellini, M.; Marchetti, A.; Ardizzoni, A.; Santoni, M. Immune-Based Combinations for the Treatment of Metastatic Renal Cell Carcinoma: A Meta-Analysis of Randomized Clinical Trials. Eur. J. Cancer 2021, 154, 120–127. [CrossRef]
6. Yang, Y. Cancer Immunotherapy: Harnessing the Immune System to Battle Cancer. J. Clin. Investig. 2015, 125, 3335–3337. [CrossRef]
7. Van den Bulk, J.; Verdegaal, E.M.; de Miranda, N.F. Cancer Immunotherapy: Broadening the Scope of Targetable Tumours. Open Biol. 2018, 8, 180037. [CrossRef]
8. Abbott, M.; Ustoyev, Y. Cancer and the Immune System: The History and Background of Immunotherapy. Semin. Oncol. Nurs. 2019, 35, 150923. [CrossRef]
9. Ascierto, P.A.; Del Vecchio, M.; Mandalà, M.; Gogas, H.; Arance, A.M.; Dalle, S.; Cowey, C.L.; Schenker, M.; Grob, J.-J.; Chiarion-Sileni, V.; et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage IIIB–C and Stage IV Melanoma (CheckMate 238): 4-Year Results from a Multicentre, Double-Blind, Randomised, Controlled, Phase 3 Trial. Lancet Oncol. 2020, 21, 1465–1477. [CrossRef] [PubMed]
10. Bajorin, D.F.; Witjes, J.A.; Gschwend, J.E.; Schenker, M.; Valderrama, B.P.; Tomita, Y.; Baniyas, I.; Lebret, T.; Shariat, S.F.; Park, S.H.; et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N. Engl. J. Med. 2021, 384, 2102–2114. [CrossRef]
11. Kelly, R.J.; Ajani, J.A.; Kuzdzal, J.; Zander, T.; Van Cutsem, E.; Piessen, G.; Mendez, G.; Feliciano, J.; Motoyama, S.; Lièvre, A.; et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N. Engl. J. Med. 2021, 384, 1191–1203. [CrossRef] [PubMed]
12. Zimmer, L.; Livingstone, E.; Hassel, J.C.; Fluck, M.; Eigentler, T.; Loquai, C.; Haferkamp, S.; Gutzmer, R.; Meier, F.; Mohr, P.; et al. Adjuvant Nivolumab plus Ipilimumab or Nivolumab Monotherapy versus Placebo in Patients with Resected Stage IV Melanoma with No Evidence of Disease (IMMUNED): A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial. Lancet 2020, 395, 1558–1568. [CrossRef]
13. Felip, E.; Altoroki, N.; Zhou, C.; Csoszi, T.; Vynnychenko, I.; Goloborodko, O.; Lufth, A.; Akopov, A.; Martinez-Marti, A.; Kenmotsu, H.; et al. Adjuvant Atezolizumab after Adjuvant Chemotherapy in Resected Stage IB–IIIA Non-Small-Cell Lung Cancer (IMpower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial. Lancet 2021, 398, 1344–1357. [CrossRef]
14. Bellmunt, J.; Hussain, M.; Gschwend, J.E.; Albers, P.; Oudard, S.; Castellano, D.; Daneshmand, S.; Nishiya, H.; Majchrowicz, M.; Degaonkar, V.; et al. Adjuvant Atezolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (IMvigor010): A Multicentre, Open-Label, Randomised, Phase 3 Trial. Lancet Oncol. 2021, 22, 525–537. [CrossRef]
15. Eggermont, A.M.M.; Blank, C.U.; Mandalà, M.; Long, G.V.; Atkinson, V.G.; Dalle, S.; Haydon, A.M.; Meshcheryakov, A.; Khattak, A.; Carlino, M.S.; et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (EORTC 1325-MG/KEYNOTE-054): Distant Metastasis-Free Survival Results from a Double-Blind, Randomised, Controlled, Phase 3 Trial. *Lancet Oncol.* 2021, 22, 643–654. [CrossRef]

16. Choueiri, T.K.; Tomczak, P.; Park, S.H.; Venugopal, B.; Ferguson, T.; Chang, Y.-H.; Hajek, J.; Symeonides, S.N.; Lee, J.L.; Sarwar, N.; et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. *N. Engl. J. Med.* 2021, 385, 683–694. [CrossRef]

17. Overwijk, W.W. Cancer Vaccines in the Era of Checkpoint Blockade: The Magic Is in the Adjuvant. *Curr. Opin. Immunol.* 2017, 47, 103–109. [CrossRef]

18. O’Donnell, J.S.; Teng, M.W.L.; Smyth, M.J. Cancer Immunoediting and Resistance to T Cell-Based Immunotherapy. *Nat. Rev. Clin. Oncol.* 2019, 16, 151–167. [CrossRef]

19. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *BMJ* 2009, 339, b2535. [CrossRef]

20. Higgins, J.P.T.; Thomas, J.; Chandler, J.; Cumpston, M.; Li, T.; Page, M.J.; Welch, V.A. *Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (Updated February 2022)*, 2nd ed.; Chichester John Wiley Sons: Chichester, UK, 2019.

21. Higgins, J.P.T.; Altman, D.G.; Gotzsche, P.C.; Juni, P.; Moher, D.; Oxman, A.D.; Savovic, J.; Schulz, K.F.; Weeks, L.; Sterne, J.A.C. The Cochrane Collaboration’s Tool for Assessing Risk of Bias in Randomised Trials. *BMJ* 2011, 343, d5928. [CrossRef]

22. Martini, A.; Fallara, G.; Pellegrino, F.; Cirulli, G.O.; Larcher, A.; Necchi, A.; Montorsi, F.; Capitanio, U. Neoadjuvant and Adjuvant Immunotherapy in Renal Cell Carcinoma. *World J. Urol.* 2021, 39, 1369–1376. [CrossRef] [PubMed]

23. Ng, G.; Xu, W.; Atkinson, V. Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy. *Curr. Oncol. Rep.* 2022. [CrossRef]

24. Donlon, N.E.; Davern, M.; Hayes, C.; Power, R.; Sheppard, A.D.; Donohoe, C.L.; Lysaght, J.; Reynolds, J.V. The Immune Response to Major Gastrointestinal Cancer Surgery and Potential Implications for Adjuvant Immunotherapy. *Crit. Rev. Oncol. Hematol.* 2022, 175, 103729. [CrossRef] [PubMed]

25. Lao, C.D.; Khushalani, N.I.; Angeles, C.; Petrella, T.M. Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better? *Am. Soc. Clin. Oncol. Educ. B* 2022, 42, 738–744. [CrossRef] [PubMed]

26. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med.* 2009, 6, e1000097. [CrossRef]